Research Article
Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy
Table 2
Patient, tumor, and treatment characteristics.
| | | Entire cohort | Diffuse progression | Limited progression (<3 sites) | | Entire cohort | Oligoprogression | Oligometastatic + progression |
| | Patients, | 108 | 74 | 34 | 23 | 11 |
| | Age at diagnoses, median (range) | 55 (22–82) years | 54 (22–80) years | 57 (26–82) years | 59 (39–82) years | 52 (26–76) years | | Age at mets | 55 (22–84) years | 55 (22–84) years | 59 (28–82) years | 60 (41–82) years | 55 (28–76) years |
| | Phenotype, (%) | | | | | | | ER(+)/PR(+)/Her2(−) | 73 (68%) | 54 (73%) | 19 (56%) | 17 (74%) | 2 (18%) | | ER(+)/PR(−)/Her2(−) | 14 (13%) | 8 (11%) | 6 (18%) | 3 (13%) | 3 (27%) | | ER(+)/PR(+)/Her2(+) | 12 (11%) | 7 (9%) | 5 (15%) | 1 (4%) | 4 (36%) | | ER(+)/PR(−)/Her2(+) | 9 (8%) | 5 (7%) | 4 (12%) | 2 (9%) | 2 (18%) |
| | Time to metastases | | | | | | | Median (range) | 1 (0–99) months | 1 (0–99) months | 10 (0–49) months | 4 (0–49) months | 10 (0–30) months | | ≤6 months from initial Dx, (%) | 63 (58%) | 46 (62%) | 17 (50%) | 13 (57%) | 4 (36%) | | >6 months from initial Dx, (%) | 45 (42%) | 28 (38%) | 17 (50%) | 10 (43%) | 7 (64%) |
| | Extent of metastases, (%) | | | | | | | ≤6 sites of disease | 30 (28%) | 15 (20%) | 15 (44%) | 4 (17%) | 11 (100%) | | >6 sites of disease | 78 (72%) | 52 (70%) | 19 (56%) | 19 (83%) | 0 (0%) |
| | Sites of disease, (%) | | | | | | | Bone | 69 (64%) | 53 (72%) | 16 (47%) | 12 (52%) | 4 (36%) | | Local/regional | 42 (39%) | 34 (46%) | 7 (21%) | 4 (17%) | 3 (27%) | | Lung/mediastinum | 37 (34% | 27 (36%) | 10 (29%) | 9 (39%) | 1 (9%) | | Liver | 34 (31%) | 22 (30%) | 12 (35%) | 8 (35%) | 4 (36%) | | Brain | 4 (4%) | 3 (4%) | 1 (3%) | 1 (4%) | 0 (0%) | | Other | 9 (8%) | 7 (9%) | 2 (6%) | 2 (9%) | 0 (0%) |
| | Prior chemotherapy, (%) | 45 (42%) | 24 (32%) | 17 (50%) | 11 (48%) | 6 (55%) | | Prior endocrine therapy, (%) | 44 (41%) | 28 (38%) | 16 (47%) | 10 (43%) | 6 (55%) |
| | Rounds of endocrine therapy, (%) | | | | | | | 1 | 57 (53%) | 47 (64%) | 10 (29%) | 5 (22%) | 5 (45%) | | 2 | 18 (17%) | 8 (11%) | 10 (29%) | 8 (35%) | 2 (18%) | | 3 | 29 (27%) | 17 (23%) | 12 (35%) | 9 (39%) | 3 (27%) | | 4 | 4 (4%) | 2 (3%) | 2 (6%) | 1 (4%) | 1 (9%) |
|
|
ER: estrogen receptor; PR: progesterone receptor; Her2: Her2neu.
|
